< 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
Interference observed with 1 or more available related molecules.
The Quantikine HS Human PlGF Immunoassay is a 3.5 hour solid phase ELISA designed to measure PlGF levels in serum and plasma. It contains E. coli-expressed recombinant human PlGF and antibodies raised against the recombinant factor. This immunoassay has been shown to quantitate recombinant human PlGF accurately. Results obtained using natural human PlGF showed linear curves that were parallel to the standard curves obtained using the Quantikine HS kit standards. These results indicate that this kit can be used to determine relative mass values for natural human PlGF.
Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
Serum, EDTA Plasma, Heparin Plasma
The recovery of PlGF spiked to levels throughout the range of the assay in various matrices was evaluated.
Average % Recovery
EDTA Plasma (n=4)
Heparin Plasma (n=4)
To assess the linearity of the assay, samples spiked with high concentrations of PlGF were serially diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Preparation and Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
PlGF (placenta growth factor) is a homodimeric growth factor that competes with VEGF for binding to VEGF R1/Flt-1. It therefore increases the availability of VEGF to bind to VEGF R2/KDR/Flk-1 and trigger angiogenesis. It can form heterodimers with some forms of VEGF and decrease the angiogenic effect of VEGF on VEGF R2. Circulating PlGF levels increase during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. PlGF induces monocyte activation and migration as well as production of inflammatory cytokines and VEGF. These activities facilitate wound, bone fracture, and cardiac repair, but also contribute to inflammation in active sickle cell disease and atherosclerosis. PlGF can also inhibit TIMP3 expression in the spleen, leading to immune triggering of hypertension.